Chemed Corporation (CHE) stock price, news, quote and history
This article provides a detailed overview of Chemed Corporation (CHE) stock, including its current price, historical data, key financial metrics, and analyst insights. It covers the company's business segments, performance against the S&P 500, earnings trends, and valuation measures.
Chemed Corporation (CHE) stock price, news, quote and history
This article provides a comprehensive overview of Chemed Corporation (CHE), including its current stock price, recent performance metrics, and key financial data. It details the company's business segments, VITAS and Roto-Rooter, and highlights analyst ratings and price targets. The information presented aims to give investors a snapshot of CHE's market position and operational details.
Chemed Corp (CHE) Stock forecasts
Argus has raised its target price for Chemed Corp (CHE) to $544.00, an increase from its current price of $507.50. Chemed Corp is described as a company that purchases, operates, and divests subsidiaries to maximize shareholder value. The report provides a quantitative analysis for investors interested in the healthcare sector.
An executive exercises 12,099 Chemed (CHE) options, with 11,160 shares delivered or withheld for costs and taxes.
Chemed EVP Spencer S. Lee exercised 12,099 stock options on September 30, 2026, at an exercise price of $445.35 per share. Concurrently, 11,160 shares were delivered or withheld to cover the purchase price and tax obligations. Following this transaction, Lee holds 16,097 options that are set to expire on October 28, 2026.
Chemed To Report Third Quarter 2026 Earnings October 27, Related Conference Call To Be Held On October 28
Chemed Corporation (NYSE: CHE) announced it will release its third-quarter 2026 financial results on Tuesday, October 27, 2026, after market close. The company will host a conference call and webcast on Wednesday, October 28, 2026, at 10 a.m. ET to discuss the results and provide a business update. Chemed operates VITAS Healthcare and Roto-Rooter.
Chemed Corp CEO Kevin J. McNamara Sells 2,000 Shares at $513.45 Average Price in September 2026
Kevin J. McNamara, President and CEO of Chemed Corporation (NYSE:CHE), sold 2,000 shares of the company's Capital Stock on September 28, 2026, at a weighted average price of $513.45 per share. This transaction, detailed in a Form 4 filing, leaves McNamara with 66,418 shares of Chemed Capital Stock. The shares were sold in multiple transactions ranging from $510.93 to $515.12.
Chemed (NYSE:CHE) Stock: Insider Kevin Mcnamara Sells 2,000 Shares
Chemed CEO Kevin Mcnamara sold 2,000 shares of the company's stock for approximately $1.03 million, reducing his direct ownership to 66,418 shares. This transaction occurred as Chemed's shares traded down, despite the company reporting better-than-expected quarterly earnings and an increased dividend. Analysts currently maintain a consensus "Hold" rating for Chemed stock.
CHE Initiates Coverage by UBS -- Price Target Announced at $650
UBS has initiated coverage on Chemed Corp (CHE) with a "Buy" rating and a price target of $650. The company is currently trading at $508.29, making it 26.3% undervalued according to GuruFocus's GF Value™ of $690.13. Chemed boasts a strong GF Score™ of 87/100 and solid financial health, despite some insider selling activity.
Chemed Corp (CHE) Stock Up 3.3% and Still Undervalued -- GF Scor
Chemed Corp (CHE) shares rose 3.3% to $512.16, placing it significantly below its GF Value™ estimate of $690.13, indicating it is undervalued by 25.8%. The company boasts a strong GF Score™ of 87/100, driven by robust profitability and valuation, despite a lower momentum rank. However, investors should note the insider selling of $9.1 million over the past year with no buying activity, which presents a potential cautious signal.
UBS initiates Chemed stock coverage with buy rating on growth outlook
UBS has initiated coverage on Chemed Corp. (NYSE:CHE) with a buy rating and a price target of $650, citing expectations for low double-digit adjusted EPS growth. The firm anticipates 19% EPS growth in 2026, followed by 10% in 2027 and 2028, driven by EBITDA growth and share repurchases. UBS views the current valuation as an attractive entry point, noting that the stock trades below its five-year average forward P/E.
UBS initiates Chemed stock coverage with buy rating on growth outlook
UBS has initiated coverage on Chemed Corp. (NYSE: CHE) with a "buy" rating and a price target of $650.00, citing expectations for low double-digit adjusted earnings per share growth. The firm projects adjusted EPS growth of 19% in 2026 and 10% in both 2027 and 2028, driven by EBITDA growth and share repurchases. Despite current market pressures on its Roto-Rooter business, UBS views Chemed's current valuation at 18 times forward price-to-earnings as an attractive entry point, especially given recent strong Q2 results and a raised outlook.
Form 144 CHEMED CORP For: 24 September By Investing.com
The article reports that a Form 144 for CHEMED CORP was filed for September 24th, 2026. This filing is a notification to the SEC of the intent to sell restricted securities.
Chemed (CHE) Buys a $60.6M Roto-Rooter Franchise. Can Ownership Lift Returns?
Chemed Corporation acquired its largest independent Roto-Rooter franchise for $60.6 million, covering California territories that serve approximately 11 million people. The acquisition is expected to leverage existing demand and the Roto-Rooter brand. The success of the investment will depend on Chemed's ability to improve operating margins, integrate the new operations efficiently, and generate sufficient cash flow to justify the purchase price.
Chemed Insider Sold Shares Worth $1,002,800, According to a Recent SEC Filing
A recent SEC filing revealed that an insider at Chemed Corporation sold shares valued at $1,002,800. This transaction occurred on September 21, 2026. The article also provides recent news about Chemed, including dividend declarations and analyst rating adjustments.
Chemed president and CEO Kevin McNamara sells $1.0m in company stock
Chemed President and CEO Kevin J. McNamara sold 2,000 shares of company stock worth over $1 million on September 18, 2026, at an average price of $501.40 per share. Following the sale, McNamara still holds 68,418 shares. The company has shown strong performance with a 34% return in six months and raised its dividend for 17 consecutive years, while also reporting strong Q2 earnings that surpassed Wall Street expectations, attributed to growth in its VITAS hospice unit and Roto-Rooter.
Chemed Corp (CHE) Insider Sale: President and CEO Kevin Mcnamara Sells 2,000 Shares
Kevin Mcnamara, President and CEO of Chemed Corp (CHE), sold 2,000 shares of the company, continuing a pattern of insider selling over the past year. While insider activity shows 13 sells and 0 buys, the stock is considered "Modestly Undervalued" by GuruFocus's GF Value, and 7 gurus hold shares, with more adding than trimming. This creates a nuanced picture for investors, suggesting personal financial planning may be a factor in the insider sale rather than a lack of confidence in the company.
Chemed (NYSE: CHE) CEO sells shares outside a preset trading plan
Chemed's president and CEO, Kevin J. McNamara, sold 2,000 shares of the company's Capital Stock on September 18, 2026, for a weighted average price of $501.40 per share. This transaction, which was not executed under a Rule 10b5-1 trading plan, leaves him with 68,418 directly held shares. The sale's impact is categorized as "Very High" and its sentiment as "Negative."
Chemed Corp (CHE) Stock Analysis: Exploring 9.51% Potential Upside and Strong Return on Equity
Chemed Corp (CHE), a company specializing in healthcare and essential services, shows a potential upside of 9.51% based on analyst target prices. The company demonstrates strong financial health with robust revenue growth, a solid return on equity of 27.11%, and a healthy free cash flow. Despite trading below its 50-day moving average, its unique diversified business model and strong fundamentals suggest a compelling investment case for long-term investors.
Chemed president and CEO Kevin McNamara sells $1.0m in company stock
Chemed Corp's President and CEO, Kevin J. McNamara, sold 2,000 shares of company stock for a total of $1,002,800. Following the sale, McNamara still holds 68,418 shares. The company has shown strong performance, with its stock returning 34% over six months and being identified as undervalued by InvestingPro.
Kevin Mcnamara Sells 2,000 Shares of Chemed (NYSE:CHE) Stock
Chemed CEO Kevin Mcnamara sold 2,000 shares of the company's stock for approximately $1.0 million, reducing his stake by 2.84%. Following the sale, Chemed's shares fell by 1.3%, though the company recently reported strong quarterly earnings that surpassed estimates and increased its quarterly dividend. Institutional investors hold a significant portion of the stock, and analysts currently have a consensus "Hold" rating with an average price target of $530.75.
103,610 Shares in Chemed Corporation $CHE Purchased by Bank of America Corp DE
Bank of America Corp DE has acquired a new stake of 103,610 shares in Chemed Corporation (NYSE:CHE) during the second quarter, valued at approximately $48.3 million, giving them a 0.79% ownership. This move comes as Chemed reported strong quarterly results, beating analyst expectations with EPS of $6.06 and revenue of $673.25 million, an 8.8% year-over-year increase, and subsequently raised its quarterly dividend. Despite these positive indicators, analysts maintain a "Hold" rating with an average price target of $530.75 for the stock.
Wall Street Zen Downgrades Chemed (NYSE:CHE) to Buy
Wall Street Zen has downgraded Chemed (NYSE:CHE) from a "strong-buy" to a "buy" rating, despite the broader analyst consensus remaining a "hold" with a $530.75 price target. The company recently exceeded earnings expectations, reporting $6.06 EPS against a $5.60 estimate and an 8.8% year-over-year revenue increase to $673.25 million. Insider selling has occurred in the past quarter, while institutional investors hold a significant majority of the stock.
What’s Behind Chemed’s (NYSE:CHE) Unusual Healthcare Mix?
Chemed Corporation (NYSE:CHE) is attracting attention due to its unusual business model, combining hospice and palliative care through VITAS Healthcare with plumbing and water restoration services via Roto-Rooter. This diversification, along with strong quarterly financial performance that surpassed market estimates and a recent dividend increase, has brought the company into focus. Its unique structure provides exposure to distinct demand patterns in both healthcare and essential home services, setting it apart in the market.
Chemed Corporation (NYSE:CHE) Given Average Recommendation of "Hold" by Brokerages
Chemed Corporation (NYSE:CHE) has received an average "Hold" recommendation from brokerages, with five out of six analysts rating the stock neutral and one recommending a buy. The average 12-month price target is $530.75. The company recently reported strong quarterly results, exceeding EPS and revenue expectations, and increased its quarterly dividend.
Chemed at jefferies healthcare conference: vitas growth offsets roto-rooter strain
Chemed Corporation presented a mixed but generally positive outlook at the Jefferies Healthcare Services and Technology Conference, highlighting strong performance from its hospice unit, VITAS, which is exceeding expectations and reducing Medicare cap risk. Conversely, its plumbing services division, Roto-Rooter, faces pressures from Google search changes that have increased marketing costs and reset its profit outlook to lower margins. Despite these challenges, Chemed is actively repurchasing shares and believes its stock is undervalued, aiming for consistent operating growth.
California State Teachers Retirement System Purchases 7,597,086 Shares of Chemed Corporation $CHE
The California State Teachers Retirement System significantly increased its stake in Chemed Corporation by purchasing 7.6 million additional shares, now owning 58.25% of the company. Chemed reported strong quarterly earnings, beating analyst expectations, and raised its quarterly dividend. Despite insider selling, institutional investors hold a substantial portion of the company, and analysts maintain a "Hold" rating with an average target price of $530.75.
Chemed Corporation to Present at the Jefferies 2026 Healthcare Services Conference
Chemed Corporation announced it will present at the Jefferies 2026 Healthcare Services and Technology Conference on September 15, 2026. The presentation will be webcast live and accessible via the company's website. Chemed operates VITAS Healthcare, a hospice care provider, and Roto-Rooter, a plumbing services provider.
Public Employees Retirement System of Ohio Makes New Investment in Chemed Corporation $CHE
The Public Employees Retirement System of Ohio has acquired 4,032 shares of Chemed Corporation (NYSE:CHE) worth approximately $1.88 million. This investment is part of broader institutional buying, with 95.85% of the company's stock now owned by institutional investors. Chemed recently reported strong quarterly earnings, increased its dividend, and provided optimistic fiscal 2026 EPS guidance, although analysts maintain a "Hold" rating.
Empowered Funds LLC Makes New Investment in Chemed Corporation $CHE
Empowered Funds LLC has acquired a new position in Chemed Corporation, purchasing 2,060 shares valued at approximately $959,000. Chemed reported strong quarterly earnings, beating consensus estimates with an 8.8% year-over-year revenue increase, and raised its quarterly dividend. The company maintains a consensus "Hold" rating from analysts with an average price target of $530.75.
Corient Private Wealth LP Invests $1.26 Million in Chemed Corporation $CHE
Corient Private Wealth LP has invested $1.26 million in Chemed Corporation by purchasing 2,704 shares in the second quarter, making them one of several institutional investors increasing their stake. Chemed exceeded Q2 earnings expectations with $6.06 EPS and $673.25 million in revenue, leading to a raised quarterly dividend and positive analyst outlooks, though insider selling has also occurred. The company projects FY 2026 EPS guidance between $25.00 and $25.75, and analysts currently hold a consensus "Hold" rating with an average price target of $530.75.
The Manufacturers Life Insurance Company Purchases New Position in Chemed Corporation $CHE
The Manufacturers Life Insurance Company recently acquired 9,475 shares of Chemed Corporation, valued at approximately $4.4 million, making them a new institutional investor in the company. Chemed exceeded quarterly earnings and revenue expectations, and analysts maintain a "Hold" rating with an average price target of $530.75. The company also increased its quarterly dividend, while insiders have sold a significant number of shares recently.
Jupiter Topco LLC Invests $7.41 Million in Chemed Corporation $CHE
Jupiter Topco LLC has acquired a new stake of $7.41 million in Chemed Corporation ($CHE) during the second quarter, purchasing 15,913 shares and now owning approximately 0.12% of the company. Chemed exceeded quarterly earnings expectations with $6.06 EPS and $673.25 million in revenue, leading analysts to maintain a "Hold" rating with a $530.75 price target. The company also increased its quarterly dividend to $0.70 per share.
Liquidity Mapping Around (CHE) Price Events
The article analyzes Chemed Corp (NYSE: CHE) based on AI models, indicating a neutral sentiment across all time horizons and suggesting a "wait-and-see" approach. It highlights compelling upside potential due to the absence of resistance levels above the current price and provides three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for different risk profiles.
Bank of New York Mellon Corp Acquires Shares of 94,045 Chemed Corporation $CHE
Bank of New York Mellon Corp acquired 94,045 shares of Chemed Corporation (NYSE:CHE) during the second quarter, valued at approximately $43.8 million, establishing a 0.72% stake in the company. Chemed recently exceeded quarterly earnings expectations with $6.06 EPS and $673.25 million in revenue, an 8.8% year-over-year increase, and increased its quarterly dividend. Analysts currently maintain a "Hold" rating for Chemed, with an average price target of $530.75, while company insiders have sold over 6,500 shares worth about $3.4 million in the last quarter.
95,136 Shares in Chemed Corporation $CHE Bought by Caisse de depot et placement du Quebec
Caisse de dépôt et placement du Québec acquired 95,136 shares of Chemed Corporation (NYSE:CHE) valued at approximately $44.3 million, representing 0.73% of the company. Other institutional investors also adjusted their positions, and insiders sold 6,537 shares worth $3.4 million in the last 90 days. Chemed exceeded Q2 earnings expectations, reported an 8.8% year-over-year revenue increase, and raised its quarterly dividend from $0.60 to $0.70 per share.
Chemed Corp CEO Kevin J. McNamara Sells 2,000 Shares at Weighted Average Price of $541.16
Kevin J. McNamara, President and CEO of Chemed Corporation, sold 2,000 shares of Chemed Capital Stock on August 21, 2026, at a weighted average price of $541.16 per share. The individual sales ranged from $539.62 to $542.53. After this transaction, McNamara retains direct ownership of 70,418 shares.
Chemed (NYSE:CHE) CEO Kevin Mcnamara Sells 2,000 Shares of Stock
Chemed CEO Kevin McNamara sold 2,000 shares of the company's stock for over $1 million, reducing his stake by 2.76%. The company recently exceeded quarterly earnings expectations, reporting $6.06 EPS against a $5.60 consensus, and raised its quarterly dividend to $0.70 per share. Analysts currently maintain a consensus "Hold" rating for Chemed with a $530.75 price target.
Chemed (NYSE: CHE) EVP sells 1,000 shares in August trade
Chemed (NYSE: CHE) Executive Vice President Spencer S. Lee sold 1,000 shares of the company's capital stock on August 21, 2026, at a price of $541.04 per share. Following this transaction, Lee directly holds 13,912 shares. This insider trade was filed as a Form 4, indicating a net sale by the executive.
Chemed president and CEO Kevin McNamara sells $1.08 million in stock
Chemed president and CEO Kevin McNamara sold 2,000 shares of company stock for $1.08 million on August 21, 2026, averaging $541.16 per share. Following the sale, McNamara directly holds 70,418 shares. The sale occurred as Chemed trades near its 52-week high, with the company also recently reporting strong Q2 earnings that surpassed expectations.
Chemed (NYSE: CHE) CEO sells 2,000 shares, keeps 70,418
Chemed (NYSE: CHE) President and CEO Kevin J. McNamara sold 2,000 shares of company stock on August 21, 2026, at a weighted average price of $541.16 per share. The transaction, classified as an open market or private sale, leaves McNamara with a direct holding of 70,418 shares. The individual trade prices for the sale ranged from $539.62 to $542.53.
Chemed Corp (CHE) Stock Analysis: Evaluating its Robust Growth Potential with a 2.11% Upside
Chemed Corp (CHE) is a prominent healthcare player with a market capitalization of $7.07 billion, operating in hospice care (VITAS) and plumbing services (Roto-Rooter). The stock is currently trading at $540.57, showing a 0.01% increase, and has a potential upside of 2.11% according to analyst ratings. Its strong financial performance is underscored by a 0.52% dividend yield, 27.11% return on equity, and $307.86 million in free cash flow, making it an attractive consideration for investors in the healthcare sector.
AQR Capital Management Expands Chemed Corp (CHE) Stake -- Shares Look 22% Undervalued on GF Value
AQR Capital Management significantly increased its stake in Chemed Corp (CHE), purchasing 556,862 shares. The stock has appreciated since the acquisition and is considered 22% undervalued based on GuruFocus's GF Value, suggesting confidence in its long-term prospects. Chemed Corp, operating in hospice care (VITAS) and plumbing services (Roto-Rooter), exhibits robust financial health and strong operational efficiency, making it an appealing consideration for long-term investors.
Chemed Corp (CHE) Investor Outlook: Exploring Growth Potential With A 3.59% Upside
Chemed Corp (NYSE: CHE), a diversified healthcare company operating through its VITAS hospice and Roto-Rooter plumbing segments, is currently trading at $532.88 with a potential upside of 3.59% based on analyst target prices. The company demonstrates strong financial health with 8.80% revenue growth, a 27.11% return on equity, and a solid free cash flow of $307.86 million. While technical indicators suggest the stock is nearing overbought territory, analyst ratings lean cautiously optimistic, highlighting Chemed's unique position in essential services and healthcare.
Focus Partners Advisor Solutions LLC Makes New $998,000 Investment in Chemed Corporation $CHE
Focus Partners Advisor Solutions LLC invested $998,000 in Chemed Corporation by purchasing 2,142 shares during the second quarter. Chemed reported strong quarterly results, exceeding earnings expectations and showing an 8.8% year-over-year revenue increase, leading the company to raise its quarterly dividend. Analysts generally hold a "Hold" rating for Chemed, with an average price target of $530.75.
Chemed Corp (CHE) Stock Forecasts
Argus has lowered its target price for Chemed Corp (CHE) to $564.00, citing the company's business activities of purchasing, operating, and divesting subsidiaries to maximize shareholder value. As of the report date, Chemed Corp's current price is $540.25. The report suggests upgrading to premium research for more detailed insights.
Chemed Corp VP Brian C. Judkins Executes Stock Option Exercise and Sells Shares on August 10, 2026
Brian C. Judkins, VP and Chief Legal Officer of Chemed Corp (NYSE: CHE), filed a Form 4 on August 10, 2026. The filing discloses that Judkins exercised stock options and subsequently disposed of shares on the same date.
Chemed Corp (CHE) legal chief exercises 6,786 options, withholds 5,878 shares
Brian C. Judkins, VP and Chief Legal Officer of Chemed Corp (CHE), exercised stock options for 6,786 shares at an exercise price of $445.35 per share. To cover the purchase and tax obligations, 5,878 shares were withheld at $548.96 per share. Following this transaction, Judkins retains 31,281 option-based shares and 3,344 shares of capital stock.
Chemed Corporation $CHE Shares Sold by Quantinno Capital Management LP
Quantinno Capital Management LP significantly reduced its stake in Chemed Corporation (NYSE:CHE) by 55.5% in the first quarter, selling 8,251 shares but still retaining 6,603 shares valued at approximately $2.49 million. This comes as Chemed reported strong quarterly earnings, beating estimates with EPS of $6.06 and an 8.8% revenue increase, along with a dividend hike to $0.70 per share. Despite institutional ownership of 95.85% and some analyst upgrades, the stock maintains a consensus "Hold" rating.
Chemed Corp stock hits 52-week high at 552.05 USD By Investing.com
Chemed Corp's stock has reached a new 52-week high of $552.05, driven by strong financial performance and investor confidence. The company reported impressive year-to-date returns of 28.75% and surpassed Q2 earnings expectations, with significant growth in its hospice unit VITAS and steady results from Roto-Rooter. InvestingPro analysis suggests the stock is currently undervalued, with subscribers having access to additional tips like the company's 17-year streak of dividend increases.
Chemed Corp stock hits 52-week high at 552.05 USD By Investing.com
Chemed Corp's stock has reached a new 52-week high of $552.05, demonstrating strong performance with a 28.75% year-to-date return and a 25.86% increase over the past year. This milestone follows the company's strong second-quarter earnings, which surpassed Wall Street expectations due to growth in its VITAS hospice unit and Roto-Rooter. InvestingPro analysis suggests the stock is undervalued, noting its 17-year streak of dividend increases.
